(c) 2024 PillSync.com

Amlodipine 5 mg

1 INDICATIONS AND USAGE Amlodipine besylate tablet, USP is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension (1.1) o Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Coronary Artery Disease (1.2) o Chronic Stable Angina o Vasospastic Angina (Prinzmetal's or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% 1.1 Hypertension Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablet, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents. 1.2 Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine besylate tablets are indicated for the symptomatic treatment of chronic stable angina. Amlodipine besylate tablets may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal's or Variant Angina) Amlodipine besylate tablets are indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, amlodipine besylate tablets are indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure.

Cipla USA Inc.


2 years ago ROUND WHITE C 127 Amlodipine 5 mg

ROUND WHITE C 127

2 years ago ROUND WHITE C 127 Amlodipine 5 mg

C 127 ROUND WHITE

16 HOW SUPPLIED/STORAGE AND HANDLING 2.5 mg Tablets

AMLODIPINE BESYLATE Tablets, USP - 2.5 mg (

AMLODIPINE BESYLATE USP equivalent to 2.5 mg of Amlodipine per tablet) are supplied as white to off white round tablets with "126" debossed on one side and "C" on other side and supplied as follows: NDC 69097-126-05 Bottle of 90 NDC 69097-126-15 Bottle of 1000 5 mg Tablets

AMLODIPINE BESYLATE Tablets, USP - 5 mg (

AMLODIPINE BESYLATE USP equivalent to 5 mg of Amlodipine per tablet) are supplied as white to off white round tablets with "127" debossed on one side and "C" on other side and supplied as follows: NDC 69097-127-05 Bottle of 90 NDC 69097-127-15 Bottle of 1000 NDC 69097-127-69 Bottle of 10000 10 mg Tablets

AMLODIPINE BESYLATE Tablets, USP - 10 mg (

AMLODIPINE BESYLATE USP equivalent to 10 mg of Amlodipine per tablet) are supplied as white to off white round tablets with "128" debossed on one side and "C" on other side and supplied as follows: NDC 69097-128-05 Bottle of 90 NDC 69097-128-15 Bottle of 1000 NDC 69097-128-69 Bottle of 10000 Storage Store at 20°C to 25°C (68°F to 77°F). [See USP controlled room temperature.] Protect from light and moisture. Manufactured by: Cipla, Ltd., Verna, Goa India Manufactured by: Cipla Ltd., MIDC Patalganaga, India Manufactured by: Cipla Ltd., Indore SEZ, Pithampur, India Manufactured for: Cipla USA, Inc. 10 Independence Boulevard, Suite 300 Warren, NJ 07059 Revised: 2/2020


More pills like ROUND C 127

Related Pills

Amlodipine 5 mg

Cipla USA Inc.

amlodipine 2.5 mg

Cipla USA Inc.

Amlodipine 10 mg

Cipla USA Inc.

amlodipine 2.5 mg

cipla usa inc.

Amlodipine 5 mg

Cipla USA Inc.

Amlodipine 10 mg

Cipla USA Inc.












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site